Abstract:Introduction: Colorectal cancer has a high prevalence and mortality rate in the United Kingdom. Cancerous colorectal lesions often bleed into the gastrointestinal lumen. The faecal immunochemical test (FIT) detects haemoglobin (Hb) in the faeces of patients and is used as a first line test in the diagnosis of colorectal cancer. Materials and Methods: A retrospective audit of all FIT performed and all colorectal cancers diagnosed in the Hull and East Riding of Yorkshire counties of the United Kingdom (population approximately 609,300) between 2018 and 2022 was conducted. FIT were performed using a HM-JACKarc analyser from Kyowa medical. The predominant symptom suggestive of colorectal cancer which prompted the FIT was recorded. Colorectal cancer was diagnosed using the gold standard of histological biopsy following colonoscopy. Results: Between 2018 and 2022, 56,202 FIT were performed on symptomatic patients. Follow on testing identified 1,511 with colorectal cancer. Of these people, only 450 people with a confirmed colorectal cancer had a FIT within the 12 months preceding their diagnosis. Of these 450 FIT results, 36 had a concentration of <10 μg/g and may be considered to be a false negative. The sensitivity of FIT in the patients identified was 92.00%. The most common reason stated by the clinician for a FIT being performed in patients with colorectal cancer was a change in bowel habits, followed by iron deficient anaemia. The number of patients diagnosed with colorectal cancer decreased in 2020, but increased significantly in 2021. Discussion: This study shows that 8.00% of people diagnosed with colorectal cancer in the Hull and East Riding of Yorkshire regions had a negative FIT. This study also shows that the SARS-CoV-2 pandemic affected the number of people diagnosed with colorectal cancer, and therefore skews the prevalence and pre-test probability of a positive test. There are many reasons why a FIT could produce a false negative result, the most likely being biological factors affecting the stability of haemoglobin within the gastrointestinal tract, or pre-analytical factors influencing faecal sampling preventing the detection of haemoglobin. Some colorectal lesions do not protrude into the gastrointestinal lumen and are less likely to bleed. Conclusion: This is the first study showing data from outside of a structured clinical trial and provides the largest study to date showing the sensitivity of FIT in a routine clinical setting. This study also provides evidence for the impact COVID-19 had on the rate of colorectal cancer diagnosis.

Diagnostic Inconsistency of Faecal Immunochemical Tests for Haemoglobin in Population Screening of Colorectal Cancer.

Predictive Power of Quantitative and Qualitative Fecal Immunochemical Tests for Hemoglobin in Population Screening for Colorectal Neoplasm

[Diagnostic Performance of Quantitative Fecal Immunochemical Test in Detection of Advanced Colorectal Neoplasia].

Yield and Effectiveness of 2-Sample Fecal Immunochemical Test-Based Screening Program for Colorectal Cancer.

Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study

One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China

Faecal immunochemical testing (FIT): sources of result variation based on three years of routine testing of symptomatic patients in English primary care

Faecal Immunochemical Test (FIT) Sensitivity; A Five Year Audit

Optimizing Sampling Device for the Fecal Immunochemical Test Increases Colonoscopy Yields in Colorectal Cancer Screening.

Head-to-head Comparison of the Test Performance of Self-Administered Qualitative Vs. Laboratory-Based Quantitative Fecal Immunochemical Tests in Detecting Colorectal Neoplasm

Analytical evaluation of eight qualitative FIT for haemoglobin products, for professional use in the UK

Comparative Study of Hypersensitive Quantitative Fecal Immunochemical Test and Qualitative Fecal Occult Blood Test for Colorectal Cancer and Advanced Adenoma

A service evaluation of the use of faecal immunochemical tests in symptomatic patients aged under 50 years presenting to primary care

Faecal haemoglobin concentration and colorectal cancer site, stage and grade in a symptomatic cohort

Faecal immunochemical tests can improve colonoscopy triage in patients with iron deficiency: A systematic review and meta-analysis

Comparative Performance of Common Fecal Immunochemical Tests : A Cross-Sectional Study

Fecal Immunochemical Test Positivity Thresholds: An International Survey of Population-Based Screening Programs

Repeat Faecal Immunochemical Testing for Colorectal Cancer Detection in Symptomatic and Screening Patients: A Systematic Review and Meta-Analysis

Understanding colorectal cancer risk for symptomatic patients in primary care: A cohort study utilising faecal immunochemical tests and blood results in England

2002 An observational study of the effectiveness of FIT test as a risk stratification tool in frail patients presenting with anaemia

Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer.